Catalyst

Slingshot members are tracking this event:

Roche's Ocrelizumab Granted Breakthrough Therapy Designation by FDA

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
RHHBY Community voting in process

Additional Information

Additional Relevant Details The FDA has granted Roche's investigational medicine ocrelizumab (OCREVUSTM), for the treatment of people with primary progressive multiple sclerosis (PPMS), breakthrough therapy designation.  "Breakthrough Therapy Designation is designed to expedite the development and review of medicines intended to treat serious or life-threatening diseases and to help ensure people have access to them through FDA approval as soon as possible."
http://www.roche.com...